Loading…

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP vaccine in a preclinical model of HER-2 positive breast cancer

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) 2024-03, Vol.200, p.113822, Article 113822
Main Authors:	Ruzzi, F., Scalambra, L., Semprini, M.S., Pittino, O.M., Cappello, C., Angelicola, S., Palladini, A., Nanni, P., Fougeroux, C., Goksøyr, L., Sander, A.F., Lollini, P.L.
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!